. Here we report the characterization of a human NK cell subset located in mucosa-associated lymphoid tissues, such as tonsils and Peyer's patches, which is hard-wired to secrete interleukin (IL)-22, IL-26 and leukaemia inhibitory factor. These NK cells, which we refer to as NK-22 cells, are triggered by acute exposure to IL-23. In vitro, NK-22-secreted cytokines stimulate epithelial cells to secrete IL-10, proliferate and express a variety of mitogenic and anti-apoptotic molecules. NK-22 cells are also found in mouse mucosa-associated lymphoid tissues and appear in the small intestine lamina propria during bacterial infection, suggesting that NK-22 cells provide an innate source of IL-22 that may help constrain inflammation and protect mucosal sites. Human NK cells have been dissected into CD56 dim and CD56 bright subsets possessing either lytic or IFN-c secretory functions 1 . Recently, a subset of tonsil NK cells was shown to express the receptor NKp44 (ref. 2) , which is not present on blood NK cells unless they are activated in vitro with IL-2 or IL-15 (ref. 3) . We noticed that NKp44 1 NK cells are present in tonsils, but not in lymph nodes ( Supplementary Fig. 1 ). Immunohistochemical and immunofluorescent analyses showed that NKp44 1 NK cells are predominantly located in the mucosa surrounding the lymphoid follicles (Fig. 1a-c) , with only a small number in the interfollicular area (data not shown). Because tonsils are associated with the oral mucosa, we conceived that NKp44 identifies a subset of NK cells preferentially situated in mucosa-associated lymphoid tissues (MALT). Indeed, we also found NKp44 1 cells in the Peyer's patches of the ileum and the appendix (Fig. 1d, e) .
Gene expression profiles of tonsil NKp44 1 and NKp44 2 NK cells (Supplementary Fig. 2 4, 5 . Flow cytometry and migration assays confirmed that a large fraction of NKp44 1 NK cells express functional CCR6 (Fig. 2a, b) . Moreover, NKp44
1 NK cells secreted more CCL20 than NKp44 2 NK cells (Fig. 2c) . Thus, NKp44 1 NK cells can contribute to CCL20 production in the mucosa, promoting their own accumulation and attracting other immune cells. The finding that the CCR6-CCL20 axis has an important role in driving the localization of NKp44 1 NK cells was corroborated by the analysis of human dermatitis with proliferation and retention of Langerhans cell in the skin 6 . Langerhans cell accumulation caused abnormal production of CCL20, resulting in extensive infiltration of NKp44 1 NK cells ( Fig. 2d- Fig. 3 ). Moreover, intracellular IFN-c was barely detectable in NKp44 1 NK cells ( Supplementary Fig. 4 ). Notably, gene chip analysis of NKp44 1 NK cells revealed production of IL-22, which is involved in mucosal defence [9] [10] [11] [12] [13] . IL-26 and leukaemia inhibitory factor (LIF), which activate epithelial cells 14 , were also increased (Supplementary Table 1 1 T cell cytokine profile [15] [16] [17] [18] [19] , NKp44 1 NK cells did not produce IL-17 (data not shown). Thus, we will refer to NKp44 1 NK cells that secrete IL-22 as NK-22 cells.
Although PMA and ionomycin stimulation exposed the unique NK-22 cytokine profile, the physiological stimuli that activate NK-22 cells were not clear. Engagement of NKp44 or other receptors with specific antibodies had no effect (data not shown). However, stimulation of tonsil NKp44 1 NK cells with a variety of inflammatory cytokines revealed that NK-22 cells are selectively and acutely responsive to IL-23 ( Fig. 3d and Supplementary Fig. 5a ). Similar results were observed for Peyer's patch NK cells ( Supplementary  Fig. 5b ). Of all NKp44 1 NK cells, only those expressing CCR6 responded to IL-23 ( Supplementary Fig. 5c ), demonstrating that NK-22 cells are a discrete subset within NKp44 1 NK cells. IL-23 did not elicit IL-17 ( Fig. 3e) . NK-22 cells were also slightly responsive to IL-6 and IL-15 (Fig. 3d, f) . IL-12, which induces IFN-c in blood NK cells, induced neither IL-22 nor IFN-c in NK-22 cells (Fig. 3f) .
In contrast, tonsil NKp44 2 NK cells did not respond to IL-23, but did react to IL-12, secreting IFN-c rather than IL-22 (Fig. 3f) . In addition, IL-15 and IL-12 induced IFN-c in NKp44
2 NK cells almost equally well (Fig. 3f) 20 . Monocytes, dendritic cells and macrophages produce IL-23 in response to microbial stimuli 21 and hence may provide a principal intramucosal source of stimuli for NK-22 cell activation. To test this hypothesis, tonsil NK cells were co-cultured with either unstimulated or activated human allogeneic monocytes. As predicted, activated LETTERS monocytes induced IL-22 production by NK-22 cells (Fig. 3g) . Culture supernatants from activated monocytes contained IL-23 and induced IL-22 secretion just like monocytes ( Supplementary Fig. 6 ).
To assess the effect of NK-22 cell-secreted cytokines on epithelial cell function, we measured proliferation and cytokine secretion of colon epithelial cells after stimulation with culture supernatant collected from activated NK-22 cells. NK-22 cell-conditioned medium induced the proliferation of epithelial cells (Fig. 4a) and the secretion of the anti-inflammatory cytokine IL-10 (Fig. 4b) . Importantly, NK-22 cellconditioned medium was more effective than recombinant IL-22 alone, consistent with a combined action of IL-22, IL-26 and possibly yet unknown factors. IL-22, IL-26 and LIF have been shown to activate signal transducer and activator of transcription 3 (STAT3) 10, 22 , a known inducer of cell survival and proliferation, as well as STAT1. Robust STAT3 and STAT1 phosphorylation was observed in epithelial cells after stimulation with NK-22 cell-conditioned medium (Fig. 4c) . To further define downstream signalling mediators induced by NK-22-derived cytokines, we obtained gene expression profiles of colon epithelial cells treated with recombinant IL-22 (Supplementary Table  2 ). IL-22-induced genes were subsequently verified in epithelial cells stimulated with NK-22 cell-conditioned medium by immunoblot and real-time PCR analyses. Notably, NK-22 cell-conditioned medium strongly induced the proto-oncogenes Bcl-3 and Bcl-6 (Supplementary Fig. 7 ). Bcl-3 interaction with NF-kB promotes the transcription of proliferation genes in response to growth signals, whereas Bcl-6 may favour proliferation by preventing terminal differentiation 23 . Furthermore, we detected transcriptional activation of genes involved in cell growth (PBEF1, also known as NAMPT), cell cycle progression (MYC) and protection from apoptotic stimuli (kinase SGK1, serine protease inhibitors SERPINA1 and SERPINA3, and GADD45G) (Supplementary Fig. 7) . Thus, NK-22 cytokines stimulate epithelial cell proliferation, secretion of IL-10 and activate a variety of mitogenic and anti-apoptotic pathways.
To identify NK-22 cells in mouse MALT, we examined NK cells in Peyer's patches of C57BL/6 mice and found two subsets:
(40-50% of total NKp46 1 cells) and Supplementary Fig. 8 ). Acute in vitro stimulation with IL-23 elicited production of IL-22 in both subsets (Fig. 5a, b) . No NK-22 cells were detectable in the lamina propria or within the intestinal epithelium under homeostatic conditions ( Supplementary  Fig. 9a ). Because IL-22 has been shown to be essential for the early host defence against Citrobacter rodentium 11 , we infected mice with C. rodentium and observed the appearance of NK-22 cells in the lamina propria 6 days after oral inoculation ( Fig. 5c and Supplementary Fig. 9b ). In recombination activating gene-2 (Rag2)-deficient mice, which lack T-cell sources of IL-22, NK-22 cells were detected in the intestinal epithelium before and after infection with C. rodentium (Supplementary Fig. 10a ) and spontaneously secreted IL-22 ex vivo after infection. Moreover, depletion of Rag2 2/2 mice with NK1.1 at the early stages of infection resulted in accelerated mortality of infected mice ( Supplementary Fig. 10b ), indicating that NK-22 may provide an innate source of IL-22 that contributes to mucosal immunity.
Finally, we investigated the developmental pathway of NK-22 cells. Several similarities between NK-22 and T H 17 cells suggest that there may be similar differentiation requirements. This was further supported by NK-22 expression of the aryl hydrocarbon receptor (AHR), ROR-a, ROR-c and IRF4 ( Supplementary Fig. 11 [17] [18] [19] , NK-22 cells are directly and acutely stimulated by IL-23. Third, blood NK cells cultured in T H 17 polarizing cytokines and AHR agonists do not acquire the ability to secrete IL-22, perhaps reflecting a distinct differentiation pathway. We suggest that after microbial challenge of mucosal barriers and the subsequent release of IL-23 by antigen-presenting cells, NK-22 cells provide a source of IL-22 and other cytokines that may help constrain inflammation and protect mucosal sites.
METHODS SUMMARY
Isolation of tonsil NK cells. Tonsils were mechanically disrupted and NK cells were pre-enriched by magnetic purification with CD56 microbeads (Miltenyi Biotec). For many experiments cells were further stained with a combination of anti-CD56, anti-CD3, anti-CD19 (Pharmingen) and anti-NKp44 antibodies and sorted either on a Moflo cell sorter (Cytomation) or a FACSVantage sorter (BD Biosciences). Reagents. Human and mouse IL-22 ELISA kits were obtained from Antigenix America. The CCL20 ELISA kit, recombinant CCL20, IL-23 ELISA kit, antihuman IL-22 antibody for intracellular staining and anti-mouse NKp46 were obtained from R&D. IL-22 and IL-1b were purchased from Peprotec. IL-22 was used at 80 ng ml 21 for stimulation of epithelial cells. IL-23 was used at 40 ng ml 21 for stimulation of NK cells, unless otherwise stated. IL-6, IL-15, IL-26, mouse and human IL-23 were purchased from R&D. Anti-IL-17A antibody was obtained from eBioscience. IL-12p70 and antibodies against IFN-c, TNF-a, GM-CSF, LIF, perforin, granzyme, CCR6, CD103, pSTAT3, pSTAT1, NK1.1, mouse CD3 and mouse CD19 were purchased from Pharmingen. Antibodies against BCL-3, BCL-6, MCL-1 and actin for immunoblotting were obtained from Santa Cruz Biotechnology. IL-10 was quantified in cell culture supernatants with the CBA human inflammation kit (Pharmingen). Anti-NKp44 and anti-CD96 antibodies were produced and conjugated in our laboratory.
